Status:
UNKNOWN
Topical Immuonosuppressant Drugs in Spring Catarrh
Lead Sponsor:
Assiut University
Conditions:
Vernal Keratoconjunctivitis
Eligibility:
All Genders
3-18 years
Phase:
NA
Brief Summary
Spring catarrh is a prevalent type of conjunctival allergic disorder in temperate countries. Topical steroids are the cornerstone management of spring catarrh beside other anti allergic drugs. However...
Detailed Description
Vernal keratoconjunctivitis (VKC) (spring catarrh) is an allergic disease that affects children and young adults and is one of the most severe forms of atopic ocular disease. Classically, the incidenc...
Eligibility Criteria
Inclusion
- Patients suffering from Vernal Keratoconjunctivitis refractory to conventional treatments (Topical Anti-histaminic agents, Mast-cell stabilizer and steroids) are included.
Exclusion
- Contact lens wearer. Patient with one functioning eye. Patients with any other active ocular inflammatory conditions. Patients with hypersentivity reaction to either Cyclosporine A or Tacrolimus. Loss of 2 or more follow up visits.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2022
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04705584
Start Date
January 1 2021
End Date
February 1 2022
Last Update
January 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University Hospital
Asyut, Egypt, 71516